Disturbances of calcium-phosphate metabolism disturbances in chronic kidney disease stage III - V


Cite item

Full Text

Abstract

Pathogenesis and treatment of calcium-phosphate metabolism disturbances in chronic kidney disease stage III - V are discussed.

References

  1. National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am. J. Kidney Dis. 2003 (suppl. 3); 42: S1-S202
  2. Ермоленко В.М. Хроническая почечная недостаточность. Нефрология: национальное руководство. Под ред. Н.А. Мухина. М.: ГЕОТАР-Медиа. 2009; 579-629
  3. Hruska K. A., Mathew S., Lund R., Qiu P., Pratt R. Hyperphosphatemia of Chronic Kidney Disease. -Kidney Int. 2008; 74(2): 148157 <http://www.pubmedcentral.nih.gov/redirect3.cgi?&&auth=0HGDgfLzGTcQrmJ_puNE7WTmDK5Sbkl0K0jhRdkj3&reftype=publisher&article-id=2735026&issue-id=181334&journal-id=319&FROM=Article%7CFront%20Matter&TO=Content%20Provider%7CArticle%7CRestricted%20Access&rendering-type=normal&&http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&retmode=ref&cmd=prlinks&id=18449174>
  4. Gutierrez O., Isacova T., Rhee E., Shan A., Holmes J., Collerone G., Juppner H., Wolf M. Fibroblast Growth factor-23 Mitigates Hyperphosphatemia But Accentuates Calcitriol Deficiency in chronic Kidney Disease. Kidney Int. 2005; 16: 2205-2215
  5. Fucumoto S. Physiological regulationand Disorders of Phosphate metabolism - Pivotal Role of Fibroblast Growth factor-23. Inter. Med. 2008; 47: 337-343
  6. Foley R.N., Parfrey P.S., Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am. J. Kidney Dis. 1998; 32:S112-S119
  7. Parfey P.S. Cardiac disease in dialysis patients: diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 2000; 5(Suppl 5): 58-68.
  8. London G. M. Cardiovascular risk in end-stage renal disease:vascular aspects. Nephrol. Dial. Transplant. 2000; 15(Suppl 5): 97-104
  9. Coresh J., Selvin E., Stevens L.A. et al. Prevalence of Chronic Kidney Disease in the United States. J. Am. Med. Assoc. 2007; 298:2038-2047
  10. Go A.S., Chertow G.M., Fan D. et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. New. Engl. J. Med. 2004; 351:1296-1305
  11. Block G.A., Hulbert-Shearon T.E., Levin N.W. et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis. 1998;.31:607-617
  12. Kestenbaum B., Sampson J.N., Rudser K.D. et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J. Am. Soc. Nephrol. 2005;.16:520-528
  13. Slinin Y., Foley R.N., Collins A.J. Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. J. Am. Soc. Nephrol. 2005; 16:1788-1793
  14. Marchais S.J., Metivier F., Guerin A.P. et al. Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. 1999; 14: 2178-2183
  15. Block G.A., Raggi P., Bellasi A. et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007; 71: 438-441
  16. Craver L., Marco M.P., Martinez I. et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges. Nephrol. Dial. Transplant. 2007; 22: 1171-1176
  17. Liu S., Tang W., Zhou J. et al. Fibroblast Growth Factor 23. Is a Counter-Regulatory Phosphaturic Hormone for Vitamin D. J. Am. Soc. Nephrol. 2006;.17:1305-1315
  18. Земченков А.Ю., Герасимчук Р.П. Активаторы рецепторов витамина D и сосудистая кальцификация (обзор литературы). Нефрол. диал. 2009; 4(11): 276-292
  19. Милованова Л.Ю., Николаев А.Ю., Милованов Ю.С. Гиперфосфатемия как фактор риска сердечно-сосудистых заболеваний у больных ХПН на хроническом гемодиализе. Нефрол. диал. 2002; 2(4):113-117
  20. Wang L., Jerosch-Herold M., Jacobs J. et al. Coronary Artery Calcification and Myocardial Perfusion in Asymptomatic Adults: The MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2006; 48: 1018-1026
  21. Pletcher M.J., Tice J.A., Pignone M. et al. Using the Coronary Artery Calcium Score to Predict Coronary Heart Disease Events: A Systematic Review and Meta-analysis. Arch. Int. Med. 2004; 164: 128.5-1292.
  22. Davies MR., Lund R.J., Hruska K.A. BMP-7 is an efficacious treatment of vascular calcification in a murine model of atherosclerosis and chronic renal failure. J. Am. Soc. Nephrol. 2003; 14: 1559-1567
  23. Davies M.R., Lund R.J., Mathew S. et al. Low turnover osteodystrophy and vascular calcification are amenable to skeletal anabolism in an animal model of chronic kidney disease and the metabolic syndrome. J. Am. Soc. Nephrol. 2005; 16: 917-928
  24. Isakova T., Gutierrez O.M. Postprandial Mineral Metabolism and Secondary Hyperparathyroidism in early CKD. J. Am. Soc. Nephrol. 2008; 19(3): 615-623
  25. Nishimura M., Tsukamoto K., Tamaki N., Kikuchi K., Iwamot N., Ono T. Risk stratification for cardiac death in hemodialysis patients without obstructive coronary artery disease. Kidney Int. 2011; 79: 363-371
  26. Razzaque M.S. FGF23-mediated regulation of systemic phosphate homeostasis Klotho an essential player? Am. J. Physiol. Renal Physiol. 2008; 19(11): 1-27
  27. Pande S., Ritter C.S., Rothstein M. et al. FGF-23 and sFRP-4 in chronic kidney disease and post-renal transplantation. Nephron Physiol. 2006; 104: 23-32
  28. Razzaque M.S. Does FGF23 toxicity influence the outcome of chronic kidney disease? Nephrol. Dial. Transplant. 2009; 24(1): 4-7.
  29. Gutiérrez O.M. Fibroblast Growth Factor 23 and Left Ventricular Hypertrophy in Chronic Kidney Disease. Circulation. 2009; 119: 2545-2552
  30. Jean G. High levels of serum FGF-23 are associated with increased mortality in long haemodialysis patients. N.D.T. 2009 24(9); 2792-2796.
  31. Gutiérrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H, Shah A., Smith K., Lee H,, Thadhani R,, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. New Engl. J. Med. 2008; 359: 584-592
  32. Gutierrez O.M. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J. Am. Soc. Nephrol. 2005; 16: 2205-2215
  33. Gutierrez O.M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N. Engl. J. Med. 2008; 359: 584-592
  34. Kawata T. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J. Am. Soc. Nephrol. 2007; 18:2683-2688
  35. Boekel G. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur. J. Endocrinol. 2008; 158:431-437
  36. Fang M.A., Glackin C.A., Sadhu A., McDougall S. Transcriptional regulation of alpha 2(I) collagen gene expression by fibroblast growth factor-2 in MC3T3-E1 osteoblast-like cells. J. Cell. Biochem. 2001; 80: 550-559.
  37. Carpenter T.O. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. . J. Clin. Endocrinol. Metab. 2005; 90: 1012-1020
  38. Sitara D. Genetic ablation of vitamin D activation pathway reverses biochemical and skeletal anomalies in Fgf-23-null animals. Am. J. Pathol. 2006; 169:2161-2170
  39. Makoto K. Klotho in chronic kidney disease-What's new? Nephrol. Dial. Transplant. 2009; 24(6): 1705-1708
  40. Sitara D. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 2004; 23:421-432
  41. Moe S.M., Duan D., Doehle B.P. et al. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int. 2003;63:1003-1011.
  42. Huang Chou-Long. Regulation of ion channels by secreted Klotho: mechanisms and implications. Kidney Int. 2010; 77: 855-860
  43. Masuyama R. Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. J. Clin. Invest. 2006; 116:3150-3159
  44. Darry L.J. Endocrine function of bone in mineral metabolism. Clin. Invest. 2008; 118(12): 3820-3828
  45. Block G.A., Brillhart S.L., Persky M.S., Amer A., Slade A.J. Efficacy and safety of SBR759, a new iron-based phosphate binder. 2010; 77: 897-901
  46. Reddy V., Symes F., Sethi N., Scally A.J., Scott F., Mumtaz R., Stoves J. Dietitian-Led Education Program to Improve Phosphate Control in a Single-Center Hemodialysis Population. 2009; 4(19): 314-320
  47. Волгина Г.В. Вторичный гиперпаратиреоз при хронической почечной недостаточности. Лечение активными метаболитами витамина D. Нефрол. диал. 2004; 2(6): 116-127
  48. Yamazaki Y. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J. Bone Miner. Res. 2008; 23: 1509-1518
  49. Shanahan C.M., Cary N.R.B., Metcalfe J.C., et al. High expression of genes for calcification-regulating proteins in human atherosclerotic placques. J. Clin. Invest. 1994; 93:2393-2402
  50. Slinin Y., Foley R.N., Collins A.J. Calcium, Phosphorus, Parathyroid Hormone, and Cardiovascular Disease in Hemodialysis Patients: The USRDS Waves 1, 3, and 4 Study. J. Am. Soc. Nephrol. 2005; 16:1788-1793

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies